Read more

May 03, 2023
1 min read
Save

Top in endocrinology: Next-gen insulin pump; weight loss with Mounjaro

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA recently approved the Medtronic MiniMed 780G system, an insulin pump that uses meal detection technology to automatically adjust basal and bolus insulin needs for people with type 1 diabetes, according to a press release.

“A lot can happen to blood sugars in the span of an hour or even just a few minutes,” Que Dallara, executive vice president of Medtronic and president of Medtronic Diabetes, said in the release. “The algorithm adapts to the user and helps compensate for everyday challenges that are quite common around mealtimes.”

Weight loss scale and tape measure 2019
Adults with overweight or obesity and type 2 diabetes achieved a mean weight loss of more than 13% after taking either 10 mg or 15 mg of tirzepatide for 72 weeks, data show. Image: Adobe Stock

It was the top story in endocrinology last week.

The second top story covered new trial results that showed Mounjaro (tirzepatide; Eli Lilly) was associated with a mean weight loss of up to 15.7% among adults with overweight or obesity plus type 2 diabetes.

Read these and more top stories in endocrinology below:

FDA approves next-generation advanced hybrid closed-loop insulin delivery system

The FDA approved an advanced hybrid-closed loop insulin pump that provides automated real-time insulin corrections for the user, according to a press release. Read more.

SURMOUNT-2: Tirzepatide confers up to 15.7% weight loss for adults with obesity, diabetes

Adults with overweight or obesity and type 2 diabetes achieved a mean weight loss of more than 13% after taking either 10 mg or 15 mg of tirzepatide for 72 weeks, according to topline results from the SURMOUNT-2 trial. Read more.

FDA clears wearable insulin pod for adults with type 2 diabetes using basal insulin

The FDA granted clearance for a stand-alone, wearable insulin delivery pod for adults aged 18 years and older with type 2 diabetes who use basal insulin daily, according to a press release. Read more.

Senate bill would cap monthly insulin costs at $35 for Americans with commercial insurance

A bill proposed in the U.S Senate would limit out-of-pocket insulin costs for Americans with diabetes who have commercial health insurance, according to a press release. Read more.

Drinking more coffee, tea, water, low-fat milk cuts mortality risk in type 2 diabetes

Adults with type 2 diabetes who drink more coffee, tea, water and low-fat milk have a lower risk for all-cause mortality, and replacing sugar-sweetened beverages with healthier drinks after diabetes diagnosis can reduce mortality risk. Read more.